The COBRA Study, a new real-world evidence study conducted by Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and St. Josef Hospital (Bochum, Germany), was presented today at the EAN Congress and offered new insights into the use of COPAXONE® (glatiramer acetate or GA) in breastfeeding mothers with multiple sclerosis (MS).
New data on the safety of COPAXONE® (glatiramer acetate) treatment in breastfeeding mothers with relapsing multiple sclerosis: the COBRA study is presented at the 7th Congress of the European Academy of Neurology (EAN)
The U.S. FDA compiles a list of off-patent drugs without an approved generic to encourage the development of copycats. Now, the Chinese authorities are rolling out a similar initiative, only with some extra incentives.
Generic versions of Teva's multi-billion-dollar per year multiple sclerosis drug Copaxone (glatiramer) are coming, but a closer look at which competitor might win the coveted 180-day exclusivity for its generic reveals an unusual and complex situation.
Copaxone maker Teva Pharmaceutical Industries Ltd. saw higher active pharmaceutical ingredient (API) sales last year.
U.S. Supreme Court Ruling on Copaxone Triggers Questions in Generics-Minded India